Dexlansoprazole Capsule, Delayed Release
Product Images NDC 62332-824

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dexlansoprazole (NDC 62332-824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Dexlansoprazole 30 mg Capsule)

Each capsule contains 30mg of dexlansoprazole as enteric-coated pellets. Store at 25°C (77°F) with excursions allowed to 59° to 86°F. Manufactured by Alembic Pharmaceuticals Limited, it is a medication in delayed-release capsules. Pharmacists should dispense the accompanying Medication Guide to each patient. This product is manufactured for Alembic Pharmaceuticals, Inc.*

FDA Label Image

30 Capsules (Dexlansoprazole 60 mg Capsule)

Each capsule contains 60mg of dexlansoprazole as enteric-coated pellets. It is a child-resistant package and should be stored at room temperature (59° to 86°F). The medication is dispensed with a medication guide and is manufactured by Alembic Pharmaceuticals Limited in Gujarat, India. The package includes 30 capsules. The product is formulated as Delayed-Release Capsules.*

FDA Label Image

Dexlansoprazole-fig1.jpg (Dexlansoprazole Fig1)

This text appears to be a chart showing the plasma concentration (in ng/mL) of Dexlansoprazole at doses of 30 mg and 60 mg over a period of time. The concentrations are shown at different time points from 12 to 24 hours.*

FDA Label Image

Dexlansoprazole-str.jpg (Dexlansoprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.